Related Experiment Videos
Recombinant interferon in advanced breast cancer.
British Journal of Cancer
|May 1, 1984
Summary
Recombinant leucocyte interferon (rIFN-alpha A) showed limited efficacy in advanced breast cancer. While initial toxicity was high, dose reduction improved tolerability, but sustained tumor regression was observed in only a few patients.
Area of Science:
- Oncology
- Immunotherapy
Background:
- Locally advanced refractory breast cancer presents a significant treatment challenge.
- Interferons are cytokines with potential anti-cancer properties.
Purpose of the Study:
- To evaluate the efficacy and toxicity of recombinant leucocyte interferon (rIFN-alpha A) in patients with advanced refractory breast cancer.
Main Methods:
- Fifteen patients received rIFN-alpha A for up to 12 weeks.
- Dosage adjustments were made to manage toxicity.
- Tumor response and side effects were monitored.
Main Results:
- Initial high toxicity was reduced by a 50% dose decrease.
- Minor side effects were universal; major CNS toxicity occurred in six patients.
- Tumor regression was seen in nine patients at 4 weeks, but only two responded at 12 weeks.
Conclusions:
- rIFN-alpha A demonstrated limited sustained efficacy in this patient group.
- Treatment response was independent of patient history or receptor status.
- Further investigation into interferon therapy for breast cancer requires careful dose optimization and patient selection.